Malignant idiopathic anaphylaxis: Three additional cases and extended evaluation

R. S. Stoloff, N. Orfan, P. A. Greenberger, L. C. Grammer, K. E. Harris, R. Patterson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Northwestern University's Division of Allergy and Immunology (NUAI) has evaluated and treated 225 patients with idiopathic anaphylaxis (IA) over a period of 16 years. Four patients have been identified with malignant IA. The term 'malignant' is used to identify those patients with the most severe form of IA that is resistant to standard therapy. The diagnosis of malignant IA is made in patients with IA whose controlling oral corticosteroid dose was not able to be reduced below 60 mg of prednisone (or its equivalent) every other day or 20 mg of prednisone (or its equivalent) every day without an exacerbation of IA. Presented here is the long-term evaluation of one patient as well as three additional patients with malignant IA managed by our service. At the time of this report we have had no deaths due to IA in patients treated with pharmacologic regimen.

Original languageEnglish (US)
Pages (from-to)37-42
Number of pages6
JournalAnnals of Allergy
Volume69
Issue number1
StatePublished - 1992

ASJC Scopus subject areas

  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Malignant idiopathic anaphylaxis: Three additional cases and extended evaluation'. Together they form a unique fingerprint.

Cite this